
|Videos|June 10, 2019
Dr. Gadgeel on Docetaxel Plus Trametinib in KRAS-Mutated Recurrent NSCLC
Author(s)Shirish M. Gadgeel, MD
In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, discusses combo docetaxel/trametinib in G12C or non-G12C KRAS mutation-positive, recurrent NSCLC.
Advertisement
In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, spoke with Cancer Network about the results of a phase II study (
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Ruxolitinib Tablets for Hematologic Malignancies
2
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
3
Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer
4
Precision Medicine and the “Slow Death” of Transplant in Lymphoma
5


















































